Entering text into the input field will update the search result below

Iovance Bio ended Q2 with $276.1M in cash; shares down 1% after hours

  • Iovance Biotherapeutics (NASDAQ:IOVA) announces that it ended Q2 with $276.1M in cash. Net loss for the quarter was $30.7M.
  • European sites activated in five countries for two clinical trials evaluating tumor-infiltrating lymphocytes. Enrollment and dosing underway in Phase 2 melanoma study.
  • Update on melanoma program (four studies) will be provided later this year.
  • Shares are down 1% after hours.

Recommended For You

About IOVA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IOVA--
Iovance Biotherapeutics, Inc.